Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L. Molinelli C, et al. Eur J Cancer. 2024 Nov 4;213:115113. doi: 10.1016/j.ejca.2024.115113. Online ahead of print. Eur J Cancer. 2024. PMID: 39536433 Free article.
Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404].
Sirico M, Jacobs F, Molinelli C, Nader-Marta G, Debien V, Dewhurst HF, Pallesch M, Merloni F, Gianni C, De Giorgi U, de Azambuja E. Sirico M, et al. Among authors: molinelli c. Crit Rev Oncol Hematol. 2024 Nov 4:104542. doi: 10.1016/j.critrevonc.2024.104542. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 39500669 No abstract available.
Practices and views about palliative care at the end of life: A survey of oncologists from the Italian region of Liguria.
Giannubilo I, Battistuzzi L, Ruelle T, Poggio FB, Buzzatti G, D'Alonzo A, Della Rovere F, Molinelli C, Razeti MG, Nardin S, Arecco L, Perachino M, Favero D, Borea R, Pronzato P, Del Mastro L, Vecchio S, Bighin C. Giannubilo I, et al. Among authors: molinelli c. Tumori. 2024 Dec;110(6):430-436. doi: 10.1177/03008916241287616. Epub 2024 Oct 14. Tumori. 2024. PMID: 39402743
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.
Poggio F, Blondeaux E, Tagliamento M, Perachino M, Nardin S, Conte B, Giuliano M, Arpino G, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Magnolfi E, Gasparro S, Fabi A, Garrone O, Alicicco MG, Urracci Y, Poletti P, Correale P, Molinelli C, Fozza A, Puglisi F, Colantuoni G, Fregatti P, Boni L, Lambertini M, Del Mastro L. Poggio F, et al. Among authors: molinelli c. ESMO Open. 2024 Aug;9(8):103650. doi: 10.1016/j.esmoop.2024.103650. Epub 2024 Aug 8. ESMO Open. 2024. PMID: 39121814 Free PMC article. Clinical Trial.
Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Martins-Branco D, Nader-Marta G, Molinelli C, Ameye L, de Azambuja E. Martins-Branco D, et al. Among authors: molinelli c. Eur J Cancer. 2024 Sep;208:114195. doi: 10.1016/j.ejca.2024.114195. Epub 2024 Jul 2. Eur J Cancer. 2024. PMID: 38996796 No abstract available.
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer.
Giannubilo I, Battistuzzi L, Blondeaux E, Ruelle T, Poggio FB, Buzzatti G, D'Alonzo A, Della Rovere F, Latocca MM, Molinelli C, Razeti MG, Nardin S, Arecco L, Perachino M, Favero D, Borea R, Pronzato P, Del Mastro L, Bighin C. Giannubilo I, et al. Among authors: molinelli c. BMC Palliat Care. 2024 May 22;23(1):129. doi: 10.1186/s12904-024-01460-0. BMC Palliat Care. 2024. PMID: 38778303 Free PMC article.
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M. Schettini F, et al. Among authors: molinelli c. Cancer. 2024 Aug 15;130(16):2746-2762. doi: 10.1002/cncr.35323. Epub 2024 May 16. Cancer. 2024. PMID: 38752572 Free article.
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Debien V, Agostinetto E, Bruzzone M, Ceppi M, Martins-Branco D, Molinelli C, Jacobs F, Nader-Marta G, Lambertini M, de Azambuja E. Debien V, et al. Among authors: molinelli c. Clin Breast Cancer. 2024 Jul;24(5):421-430.e3. doi: 10.1016/j.clbc.2024.02.012. Epub 2024 Feb 21. Clin Breast Cancer. 2024. PMID: 38514306 Clinical Trial.
30 results